SEATTLE, Oct. 25, 2018 /PRNewswire/ -- CTI BioPharma
Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that
management plans to report its third quarter 2018 financial results
on Thursday, November 1, 2018, after the close of the U.S.
financial markets. Following the announcement, members of the
management team will host a webcast conference call to discuss the
results and provide a general corporate update at 4:30 p.m.
ET (1:30 p.m. PT). Access to the
event can be obtained as follows:
Thursday, November 1, 2018
1:30 p.m. PT/4:30 p.m. ET/10:30 p.m.
CET
1-877-260-1479 (domestic)
+1 334-323-0522 (international)
To access the live audio webcast or the subsequent archived
recording, visit CTI BioPharma's website, www.ctibiopharma.com.
Webcast and telephone replays of the conference call will be
available at approximately two hours after completion of the call.
Callers can access the replay by dialing 1-888-203-1112 (domestic)
or +1 719-457-0820 (international). The access code for the replay
is 4559931. The telephone replay will be available until
Thursday, November 8, 2018.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on
the acquisition, development and commercialization of novel
targeted therapies covering a spectrum of blood-related cancers
that offer a unique benefit to patients and healthcare providers.
The CTI BioPharma lead product candidate, pacritinib, is being
developed for the treatment of patients with myelofibrosis. CTI
BioPharma is headquartered in Seattle,
Washington.
CTI BioPharma Investor Contacts:
Julia Balanova (investors)
+1 646 378 2936
jbalanova@troutgroup.com
Rich Allan (media)
+1 646-378-2958
rallan@troutgroup.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-third-quarter-2018-financial-results-on-november-1-2018-300732337.html
SOURCE CTI BioPharma Corp.